Catalent, Inc.

NYSE:CTLT Stock Report

Market Cap: US$11.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Catalent Past Earnings Performance

Past criteria checks 0/6

Catalent's earnings have been declining at an average annual rate of -53.1%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 8.7% per year.

Key information

-53.10%

Earnings growth rate

-52.98%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate8.66%
Return on equity-11.66%
Net Margin-9.34%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Seeking Alpha • Jun 25

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Summary Catalent's stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval. Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candidates in their pipeline. Thus, Elevidys's monopoly could be under a threat. Based on my technology assessment, only two product candidates have the potential to disrupt Elevidys monopoly in the next two to three years. Thus, I consider that CTLT’s and SRPT’s revenue driven by Elevidys is not only safe, but poised to grow given the label expansion in the U.S. Read the full article on Seeking Alpha
Seeking Alpha • Feb 07

Catalent - Novo Holdings Merger: Attractive Spread

Summary We anticipate an FTC review for the Novo Holdings acquisition of Catalent, Inc. but see no grounds for blocking. Timetable risk due to regulatory approval under HSR Act. Attractive 10.2% gross spread with favourable probability of closing. Read the full article on Seeking Alpha
Seeking Alpha • Dec 13

Catalent: Debt Remains An Overhang

Summary Today, we revisit drug manufacturer Catalent, Inc., which has expanded its board membership at the behest of activist investor Elliott Management. Analysts remain skeptical about Catalent's turnaround story, but the company has made progress and has brought in new directors and executives. An updated analysis of Catalent, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 04

Catalent Remains Overvalued

Summary Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported a 3% increase in revenue for the quarter-ended June 2023, but Biologics revenue was down 37% year-over-year. Catalent's margins have weakened, with gross profit down 49% year-over-year and EBITDA down over 90% year-over-year. Catalent trades at nearly 18x forward EBITDA. Catalent is overvalued, time to sell the stock. Read the full article on Seeking Alpha
Seeking Alpha • Jul 31

Catalent: Myriad Issues To Fix

Summary Today, we take a look at Catalent, a drug manufacturer that has been beset by myriad issues over the past year resulting in a 55% drop in the stock. The company has recently drawn the interest of activist investor Elliott Management, meaning significant changes could be ahead. Will this halt the decline in the shares? An investment analysis on Catalent follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Why did Catalent stock soar today? Potential takeover by Danaher

Catalent closed Monday up ~20% on Monday following a report over the weekend that Danaher (NYSE:DHR) was interested in acquiring the contract manufacturer. BofA Securities analyst Michael Ryskin said that the premium Danaher (DHR) would have to pay for such a deal is "up for debate." He has Danaher (DHR) as a buy. Meanwhile, Jefferies' David Windley, who rates both companies a buy, said a deal could value Catalent (NYSE:CTLT) at ~$93/share. Seeking Alpha's Quant Rating views Catalent (CTLT) and Danaher (DHR) as a hold.

Revenue & Expenses Breakdown

How Catalent makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:CTLT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,422-4139810
30 Jun 244,381-1,0439350
31 Mar 244,135-1,1768970
31 Dec 234,098-1,3028630
30 Sep 234,223-1,0158390
30 Jun 234,263-2568390
31 Mar 234,495218400
31 Dec 224,7313898660
30 Sep 224,7993998670
30 Jun 224,8024838440
31 Mar 224,7034858030
31 Dec 214,4835617680
30 Sep 214,1775447060
30 Jun 213,9985296870
31 Mar 213,7574946580
31 Dec 203,4652896230
30 Sep 203,2752505980
30 Jun 203,0941735770
31 Mar 202,8721045621
31 Dec 192,7291245542
30 Sep 192,6311385353
30 Jun 192,5181325120
31 Mar 192,4781494894
31 Dec 182,4881364755
30 Sep 182,471654665
30 Jun 182,463844596
31 Mar 182,395634307
31 Dec 172,300704137
30 Sep 172,1771093967
30 Jun 172,0751103967
31 Mar 171,9911063737
31 Dec 161,896913657
30 Sep 161,8671043628
30 Jun 161,8481123518
31 Mar 161,82620734610
31 Dec 151,83522833310
30 Sep 151,83624432711
30 Jun 151,83121232512
31 Mar 151,8408631514
31 Dec 141,8476232015
30 Sep 141,832-331817
30 Jun 141,8281931718
31 Mar 141,813232817
31 Dec 131,807-2032616

Quality Earnings: CTLT is currently unprofitable.

Growing Profit Margin: CTLT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CTLT is unprofitable, and losses have increased over the past 5 years at a rate of 53.1% per year.

Accelerating Growth: Unable to compare CTLT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTLT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).

Return on Equity

High ROE: CTLT has a negative Return on Equity (-11.66%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 04:54
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Catalent, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanGoldman Sachs
Tycho PetersonJ.P. Morgan
Rachel Vatnsdal OlsonJ.P. Morgan